Peptide activating macrophages

Immunomodulation provides new therapeutic opportunities through the re-engagement of the immune system against body dysfunction (pathogen infection, oncogenesis, etc.). In particular, macrophage polarization enhances phagocytic capacity as body’s first line of defence.

**DESCRIPTION**

• Naturally occurring recombinant peptide:
  - Able to activate macrophage’s cytotoxic functions against pathogens recognized by type C lectin receptors (bacteria, fungi, yeast, parasites) and tumor cells
  - Enabling the production of pro-inflammatory cytokines
  - Displaying no direct microbicide activity
  - Depicting no evident cytotoxicity (on human erythrocytes and monocytes)

• *In vitro* and *in vivo* efficacy data on murine model of *Candida albicans*

• *In vitro* efficacy data on lymphoma model

**APPLICATIONS**

• Anti-infectious agent: bacteria, fungi, yeast, parasites

• Anti-tumor agent

• Pro-inflammatory agent

**INTELLECTUAL PROPERTY**

• Patent pending

**COMPETITIVE ADVANTAGES**

• Specific immunomodulation action limiting the rise of resistance

• Potential of synergetic action with existing drugs

• Short sequence peptide:
  - Simple to manufacture
  - Cheap

**DEVELOPMENT STAGE**

• Experimental proof of concept

**LABORATORY**

• BTBS, Pharma-Dev and DC2N laboratories

**CONTACT**

T. +33 (0)5 62 25 50 60
sante@toulouse-tech-transfer.com
www.toulouse-tech-transfer.com

* Technology requiring license rights.

TTT_132. Non contractual document. All rights reserved. – July 2017.